Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still flogging this eh, Bruce? Aren't you busy in court?
Definitely a rational and timely approval driven by necessity. This approach can arguably apply across the board in many if not all pending matters which involve Enhanze.
Good stuff.
With bonds yielding .5% the search for yield is a key driver in this market. Anybody remember what eps guidance is for this year. I think it was
$.60 per share (going from memory). Looking at HALO as a quasi dividend type investment, that means that $30 per share would equate to a 2% return. Not too shabby in this market. So IMHO $30 is fair value right now just based on this years guidance. Next year's is sure to be significantly larger, assuming new deals are in the offing.
Opposing (or confirming) thoughts are welcome.
-Fritz
Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® In...
June 13 2020 - 07:09AM
PR Newswire (US)
Print
SAN DIEGO, June 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase III ANDROMEDA (AMY3001) study of subcutaneous (SC) daratumumab utilizing ENHANZE® in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly diagnosed light-chain (AL) amyloidosis at the 25th Annual Congress of the European Hematology Association. Janssen reported that the study met the primary endpoint of percentage of patients with hematologic complete response. Additional information can be accessed here.
"We are excited that the subcutaneous formulation of daratumumab utilizing ENHANZE® has demonstrated positive results in a potentially new indication addressing an underserved population with limited treatment options," said Dr. Helen Torley.
Thanks for posting that, Dew. EOM
Interesting, and comports with my theory of an impending deal announcement.
Great. I'm guessing the news didn't make it into Helen's talk earlier today.
This discussion does raise an interesting proposition, i.e., that the safety and efficacy profile of Enhanze is by now so well established that the FDA would likely grant a significantly more streamlined approval process than in years passed, whether for Remdesivir or any other new co-formulation.
Low volume confirms consolidation here, IMHO. Deals are in the works and judging from Helen's comments (in so far as I remember them), some of them are not in the early phases. She was pretty emphatic without giving any details. In any event, consolidation at $24 is fin with me.
-Fritz
Good point but I appreciate that they are not a pumping operation.
-Fritz
Not to mention a new deal which sounds imminent.
Hedgers gonna hedge.
BMO reiterates outperform raises PT to $35. (Note: Cantor's PT was $39 and this was earlier in May).
http://quotes.benzinga.com/quote/HALO
Bingo!
…“I will be on the line with everyone else,” he wrote. “If anyone is arrested, I ask that it only be me.”
Personally I thought Helen's presentation was very bullish.
-Fritz
Thanks for the correction. I had a vague recollection that the stock had broken $25 some years ago but the Yahoo chart said differently so I went with that. Next time I'll trust my memory. LOL
-Fritz
Helen was practically promising at least one new deal soon. She has done this before and has delivered. Stay tuned.
-Fritz
New all time high today.
Home delivery of critical medicines like this one are right on time here in the Covid-19 era.
Thanks, Dew. EOM
Which is the superior product?
Cantor reiterates, raises PT to $39
https://www.benzinga.com/stock/halo/
Helen will explain it all on May 11th.
Theoretically yes, but the PR is really highlighting the benefits that differentiate the old from the new.
As seen in the pivotal study supporting the approval, this reduction in infusion time from hours to minutes led to higher satisfaction levels for patients and in addition, infusion-related reactions were both mild and significantly reduced with this formulation of daratumumab.
This should kick the door wide open for a steady stream of new collaborations.
That's impressive.
And even now at 4:45PM the news has not been disseminated widely.
May 1st, just like the man said.
Good news from Europa. What makes you change your timeline?
It's definitely breaking out, these figures are no longer just 52 week highs, but now they have reached all-time high category.
Meanwhile there's a little Darzalex news for ya.
Absent buyout considerations, HALO is well on the way to being a dividend generator. In today's world, a steady secure $1 per share would support a stock price of as much as $50 since that translates into a 2% yield.
How soon do you think we get to that figure?
-Fritz
New 52 week high again.
When we had previously talked about this, you convinced me to up my projected sale price. Darzalex alone justifies the current price, IMHO. Add whatever you think is rational on top of that. I'd say another 20 bucks, so somewhere between $40 and $50 would do it. What is your opinion?
On the other hand, my buyout theory might be all wet. Another cause might simply lie in the possibility that the buying is just the IBB forced to pick up shares as money pours into the sector. The float is small, as I figure about 90% of the shares are in the hands of institutions, So forced buying is going to be expensive. Do you think this might be it? I really don't know.
Well, it's only speculation, of course, but I'm betting that the company has found a buyer.
New 52 week high this morning. Impressive.
Things that make you go "hmmmmm...."
Yes, I had originally thought HALO was just drifting up with the sector but you're right that the bid remains today despite stiff headwinds. In addition to Darzalex the company reports first week of May and that might be a factor also, since there is a chance that the write-downs of the recent reorganization are behind us and the bottom line might prove to finally be an eye-catcher.
What do you think of that last point?
-Fritz
Exactly. Still scratching my head over Feuerstein getting so excited. He knows all of this and yet was banging the drum like all get out. Smell something fishy?